Research & Consultant Companies

The European Union has taken a significant step in addressing rare diseases, specifically targeting hepatitis E. Pharmadev Healthcare Ltd's ribavirin has been granted orphan...

A breakthrough has been realized for those suffering from Charcot-Marie-Tooth disease (CMT), as the European Medicines Agency (EMA) grants orphan designation to a new...

In a significant move to address the challenges of myasthenia gravis, the European Medicines Agency (EMA) has awarded orphan designation to telitacicept. This decision...

The European Medicines Agency (EMA) has extended a new lifeline for patients struggling with myelodysplastic syndromes. On July 18, 2025, the agency officially designated...

The European Union recently took a significant step in the field of rare diseases by designating onlicromanol hydrochloride as an orphan medicinal product. Offered...

A major stride towards treating one of the most challenging cancers, pancreatic cancer, is on the horizon as the European Union recently granted orphan...

Innovative medical advancements continue to push the boundaries of treatment options, paving the way for hope in rare diseases through strategic scientific and regulatory...

The European Medicines Agency (EMA) has officially designated Beta-lapachone as an orphan medicinal product for treating primary sclerosing cholangitis (PSC). This recognition paves the...

Roca Therapeutics has received orphan designation from the European Medicines Agency (EMA) for its innovative treatment targeting radiation-induced maculopathy. This designation, assigned on June...

The European Medicines Agency (EMA) has officially designated a new drug for acute myeloid leukaemia (AML) as an orphan medicinal product, marking a significant...

A promising new therapy targeting Netherton syndrome has been granted orphan designation by the European Medicines Agency (EMA). This designation, awarded on June 20,...

The European Medicines Agency (EMA) has officially designated Zanidatamab as an orphan medicinal product for treating biliary tract cancer, marking a significant advancement in...

The European Medicines Agency (EMA) awarded orphan designation to a groundbreaking monoclonal antibody aimed at treating osteogenesis imperfecta, a rare genetic bone disorder. This...

The European Medicines Agency (EMA) has officially designated bezuclastinib as an orphan medicinal product for treating mastocytosis as of June 20, 2025. This recognition...

Propharma Group The Netherlands B.V. has achieved a significant milestone by obtaining orphan designation from the European Medicines Agency (EMA) for its innovative treatment...